DuPont Merck Pharmaceutical and Scios Inc have announced the signing ofan agreement establishing a research collaboration into Alzheimer's disease, with the initial focus being on using Scios' high-throughput screening systems to identify useful DuPont Merck compounds.
Under the terms of the agreement, DuPont Merck has agreed to purchase $3 million of Scios common stock, and will make milestone and royalty payments. Additional financial terms of the deal were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze